

QUANTITY LIMIT CRITERIA

BRAND NAME (generic)

CINVANTI
(aprepitant)

EMEND
(aprepitant)

EMEND INJECTION
(fosaprepitant dimeglumine)

VARUBI
(rolapitant)

Status: CVS Caremark Criteria
Type: Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Cinvanti (aprepitant) injectable emulsion

Cinvanti, in combination with other antiemetic agents, is indicated in adults for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use

- Cinvanti has not been studied for the treatment of established nausea and vomiting.

Emend (aprepitant) capsules and oral suspension

Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

Emend for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Emend capsules, in combination with other antiemetic agents, is indicated in patients 12 years of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Prevention of Postoperative Nausea and Vomiting (PONV)

Emend capsules are indicated in adults for the prevention of postoperative nausea and vomiting.

Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.
- Chronic continuous administration of Emend is not recommended because it has not been studied and because the drug interaction profile may change during chronic continuous use.

Emend (fosaprepitant dimeglumine) for injection

Emend for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.

Varubi

Varubi is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

REFERENCES

1. Cinvanti [package insert]. San Diego, CA: Heron Therapeutics, Inc.; October 2018.
2. Emend capsules and oral suspension [package insert]. Whitehouse Station, NJ: Merck and Co., Inc; May 2017.
3. Emend for injection [package insert]. Whitehouse Station, NJ: Merck and Co., Inc; March 2018.
4. Varubi [package insert]. Waltham, MA: Tesaro, Inc; March 2018.
5. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed January 2019.
6. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed January 2019.
7. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemesis. Version 3.2018, June 11, 2018. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#detection. Accessed January 2019.

LIMIT CRITERIA

Drug	1 Month Limit and 3 Months Limit*
Cinvanti 130 mg Injection (Single-Dose Vial)	2 vials / 21 days
Emend 80 mg Capsule	4 capsules / 21 days
Emend 125 mg Capsule	2 capsule / 21 days
Emend 125 mg-80 mg Capsules (Tri-pack contains one 125 mg capsule and two 80 mg capsules)	2 packs / 21 days
Emend 125 mg for Oral Suspension (Single-Dose Kit contains 125 mg / 5 mL)	6 kits / 21 days
Emend 150 mg Injection (Single-Dose Vial)	2 vials / 21 days
Varubi 90 mg Tablet (Single Dose Package contains two 90 mg tablets as one set of twinned blisters)	2 packs/ 21 days
Varubi 166.5 mg Injection (Single-Dose Vial)	2 vials / 21 days

*** These drugs are indicated for short-term acute use; therefore, the mail limit will be the same as the retail limit.**
The duration of 21 days is used for a 28-day fill period.

Drug	1 Month Limit and 3 Months Limit**
Emend 40 mg Capsule	3 capsules / 6 months

**** These drugs are indicated for short-term acute use; therefore, the mail limit will be the same as the retail limit.**